EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial

Ann H Klopp iD, Danielle Enserro, Matthew Powell iD, Marcus Randall iD, Julian C Schink iD, Robert S Mannel, Laura Holman, David Bender iD, Christina L Kushnir, Floor Backes iD, Susan L Zweizig iD, Steven Waggoner und 8 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.23.01279 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Ann H Klopp und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Cisplatin, Neoplasm Recurrence, Local, Chemoradiotherapy. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pelvic recurrence is a frequent pattern of relapse for women with endometrial cancer. A randomized trial compared progression-free survival (PFS) after treatment with radiation therapy alone as compared with concurrent chemotherapy. MATERIALS AND METHODS Between February 2008 and August 2020, 165 patients were randomly assigned 1:1 to receive either radiation treatment alone or a combination of chemotherapy and radiation treatment. The primary objective of this study was to determine whether chemoradiation therapy was more effective than radiation therapy alone at improving PFS. RESULTS The majority of patients had low-grade (1 or 2) endometrioid histology (82%) and recurrences confined to the vagina (86%). External beam with either the three-dimensional or intensity modulated radiation treatment technique was followed by a boost delivered with brachytherapy or external beam. Patients randomly assigned to receive chemotherapy were treated with once weekly cisplatin (40 mg/m 2 ). Rates of acute toxicity were higher in patients treated with chemoradiation as compared with radiation treatment alone. Median PFS was longer for patients treated with radiation therapy alone as compared with chemotherapy and radiation (median PFS was not reached for RT v 73 months for chemoradiation, hazard ratio of 1.25 (95% CI, 0.75 to 2.07). At 3 years, 73% of patients treated definitively with radiation and 62% of patients treated with chemoradiation were alive and free of disease progression. CONCLUSION Excellent outcomes can be achieved for women with localized recurrences of endometrial cancer when treated with radiation therapy. The addition of chemotherapy does not improve PFS for patients treated with definitive radiation therapy for recurrent endometrial cancer and increases acute toxicity. Patients with low-grade and vaginal recurrences who constituted the majority of those enrolled are best treated with radiation therapy alone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Endometrial NeoplasmsCisplatinNeoplasm Recurrence, LocalChemoradiotherapyHumansFemaleMiddle AgedAgedProspective StudiesProgression-Free SurvivalAdultBrachytherapyAntineoplastic Agents

Substanzen

CisplatinAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Clinical Trials Development Division, Roswell Park Comprehensive Cancer Center, Buffalo, NY.
  • Washington University School of Medicine, Obstetrics & Gynecology, St Louis, MO.
  • University of Kentucky, Radiation Oncology, Lexington, KY.
  • Cancer Treatment Centers of America, City of Hope, Gynecologic Oncology, Chicago, IL.
  • University of Oklahoma Health Sciences, Oklahoma City, OK.

ORCID-Profile: Ann H Klopp, Matthew Powell, Marcus Randall, Julian C Schink, David Bender, Floor Backes, Susan L Zweizig, Kristin A Bradley, Lana DeSouza Lawrence, William Small, Higinia R Cardenes, David S Miller

Förderung

  • NCI NIH HHS

Zitieren

APA

Klopp, A. H., Enserro, D., Powell, M., Randall, M., Schink, J. C., Mannel, R. S., Holman, L., Bender, D., Kushnir, C. L., Backes, F., Zweizig, S. L., Waggoner, S., Bradley, K. A., Lawrence, L. D., Hanjani, P., Darus, C. J., Small, W., Cardenes, H. R., Feddock, J. M., & Miller, D. S. (2024). Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.23.01279

Vancouver

Klopp AH, Enserro D, Powell M, Randall M, Schink JC, Mannel RS, et al. Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.23.01279

BibTeX
@article{Klopp2024,
  author = {Klopp, Ann H and Enserro, Danielle and Powell, Matthew and Randall, Marcus and Schink, Julian C and Mannel, Robert S and Holman, Laura and Bender, David and Kushnir, Christina L and Backes, Floor and Zweizig, Susan L and Waggoner, Steven and Bradley, Kristin A and Lawrence, Lana DeSouza and Hanjani, Parviz and Darus, Christopher J and Small, William and Cardenes, Higinia R and Feddock, Jonathan M and Miller, David S},
  title = {Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.23.01279}
}
Kostenlos starten →